251 related articles for article (PubMed ID: 37076759)
1. Predictors of thyroid adverse events during cancer immunotherapy: a real-life experience at a single center.
Ruggeri RM; Spagnolo CC; Alibrandi A; Silvestris N; Cannavò S; Santarpia M
J Endocrinol Invest; 2023 Nov; 46(11):2399-2409. PubMed ID: 37076759
[TBL] [Abstract][Full Text] [Related]
2. Higher baseline TSH levels predict early hypothyroidism during cancer immunotherapy.
Luongo C; Morra R; Gambale C; Porcelli T; Sessa F; Matano E; Damiano V; Klain M; Schlumberger M; Salvatore D
J Endocrinol Invest; 2021 Sep; 44(9):1927-1933. PubMed ID: 33576954
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non-Small Cell Lung Cancer.
Luo J; Martucci VL; Quandt Z; Groha S; Murray MH; Lovly CM; Rizvi H; Egger JV; Plodkowski AJ; Abu-Akeel M; Schulze I; Merghoub T; Cardenas E; Huntsman S; Li M; Hu D; Gubens MA; Gusev A; Aldrich MC; Hellmann MD; Ziv E
Clin Cancer Res; 2021 Sep; 27(18):5131-5140. PubMed ID: 34244291
[TBL] [Abstract][Full Text] [Related]
4. The Predictive Model Construction for Immune-Related Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immunotherapy.
Gao W; Liu Q; Zhou Y; Yang M; Yu Y
Technol Cancer Res Treat; 2023; 22():15330338231206705. PubMed ID: 37927008
[TBL] [Abstract][Full Text] [Related]
5. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment.
Muir CA; Clifton-Bligh RJ; Long GV; Scolyer RA; Lo SN; Carlino MS; Tsang VHM; Menzies AM
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3704-e3713. PubMed ID: 33878162
[TBL] [Abstract][Full Text] [Related]
6. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
[TBL] [Abstract][Full Text] [Related]
7. [The association between baseline TPOAb and/or TgAb positivity and thyroid immune-related adverse events in patients with malignancies following treatment with immune checkpoint inhibitors].
Gao Y; Ye T; Wu LG; Xu Y; Wang X; Cheng XQ; Zhang YL; Wang YY; Fan XR; Zhao HT; Liu H; Chai XF; Zhang L; Wang MZ; Li NS; Lian XL
Zhonghua Yi Xue Za Zhi; 2024 Mar; 104(12):963-969. PubMed ID: 38514346
[No Abstract] [Full Text] [Related]
8. Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs).
Daban A; Gonnin C; Phan L; Saldmann A; Granier C; Lillo-Lelouet A; Le Beller C; Pouchot J; Weiss L; Tartour E; Fabre E; Medioni J; Oudard S; Vano YA; Dragon-Durey MA; Simonaggio A
Oncoimmunology; 2023; 12(1):2204754. PubMed ID: 37187974
[TBL] [Abstract][Full Text] [Related]
9. Quantitation of cardiac troponin I in cancer patients treated with immune checkpoint inhibitors: a case-control study.
Ulndreaj A; Brinc D; Altan M; Pons-Belda OD; Fernandez-Uriarte A; Mu-Mosley H; Fattah F; von Itzstein MS; Soosaipillai A; Kulasingam V; Palaskas NL; Gerber DE; Diamandis EP; Heymach JV; Prassas I
Clin Chem Lab Med; 2023 Jan; 61(1):154-161. PubMed ID: 36287134
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy as second-line treatment and beyond for non-small cell lung cancer in a single center of China: Outcomes, toxicities, and clinical predictive factors from a real-world retrospective analysis.
Chen M; Li Q; Xu Y; Zhao J; Zhang L; Wei L; Zhong W; Wang M
Thorac Cancer; 2020 Jul; 11(7):1955-1962. PubMed ID: 32468726
[TBL] [Abstract][Full Text] [Related]
11. Tumor PD-L1 expression and molecular profiling are not associated with immune checkpoint inhibitor-induced thyroid dysfunction in advanced NSCLC patients.
Horesh A; Pollack R; Nechushtan H; Dresner-Pollak R; Neuman T
Pathol Oncol Res; 2023; 29():1610951. PubMed ID: 37139142
[No Abstract] [Full Text] [Related]
12. Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States.
Yang F; Shay C; Abousaud M; Tang C; Li Y; Qin Z; Saba NF; Teng Y
J Exp Clin Cancer Res; 2023 Jan; 42(1):4. PubMed ID: 36600271
[TBL] [Abstract][Full Text] [Related]
13. Thyroid dysfunction after immune checkpoint inhibitor treatment in a single-center Chinese cohort: a retrospective study.
Wu L; Xu Y; Wang X; Cheng X; Zhang Y; Wang Y; Fan X; Zhao H; Liu H; Chai X; Zhang L; Wang M; Li N; Pan H; Lian X
Endocrine; 2023 Jul; 81(1):123-133. PubMed ID: 36867366
[TBL] [Abstract][Full Text] [Related]
14. Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer.
Grangeon M; Tomasini P; Chaleat S; Jeanson A; Souquet-Bressand M; Khobta N; Bermudez J; Trigui Y; Greillier L; Blanchon M; Boucekine M; Mascaux C; Barlesi F
Clin Lung Cancer; 2019 May; 20(3):201-207. PubMed ID: 30442524
[TBL] [Abstract][Full Text] [Related]
15. Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study.
Cortellini A; Buti S; Santini D; Perrone F; Giusti R; Tiseo M; Bersanelli M; Michiara M; Grassadonia A; Brocco D; Tinari N; De Tursi M; Zoratto F; Veltri E; Marconcini R; Malorgio F; Garufi C; Russano M; Anesi C; Zeppola T; Filetti M; Marchetti P; Botticelli A; Antonini Cappellini GC; De Galitiis F; Vitale MG; Sabbatini R; Bracarda S; Berardi R; Rinaldi S; Tudini M; Silva RR; Pireddu A; Atzori F; Chiari R; Ricciuti B; Iacono D; Migliorino MR; Rossi A; Porzio G; Cannita K; Ciciarelli V; Fargnoli MC; Ascierto PA; Ficorella C
Oncologist; 2019 Jun; 24(6):e327-e337. PubMed ID: 30796151
[TBL] [Abstract][Full Text] [Related]
16. Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors.
Kurimoto C; Inaba H; Ariyasu H; Iwakura H; Ueda Y; Uraki S; Takeshima K; Furukawa Y; Morita S; Yamamoto Y; Yamashita S; Katsuda M; Hayata A; Akamatsu H; Jinnin M; Hara I; Yamaue H; Akamizu T
Cancer Sci; 2020 May; 111(5):1468-1477. PubMed ID: 32086984
[TBL] [Abstract][Full Text] [Related]
17. Clinical Features, Survival, and Burden of Toxicities in Survivors More Than One Year After Lung Cancer Immunotherapy.
Hsu ML; Murray JC; Psoter KJ; Zhang J; Barasa D; Brahmer JR; Ettinger DS; Forde PM; Hann CL; Lam VK; Levy B; Marrone KA; Patel T; Peterson V; Sagorsky S; Turner M; Anagnostou V; Naidoo J; Feliciano JL
Oncologist; 2022 Nov; 27(11):971-981. PubMed ID: 35972337
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-10 Is a Promising Marker for Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer Receiving Immunotherapy.
Wang H; Zhou F; Zhao C; Cheng L; Zhou C; Qiao M; Li X; Chen X
Front Immunol; 2022; 13():840313. PubMed ID: 35222434
[TBL] [Abstract][Full Text] [Related]
19. Nivolumab-induced thyroid dysfunction in patients with lung cancer.
Ramos-Levi AM; Rogado J; Sanchez-Torres JM; Colomer R; Marazuela M
Endocrinol Diabetes Nutr (Engl Ed); 2019 Jan; 66(1):26-34. PubMed ID: 29910159
[TBL] [Abstract][Full Text] [Related]
20. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
